Although all large HFpEF trials addressing renin-angiotensin-aldosterone system (RAAS) inhibitors failed to reach statistical significance for the primary outcome, many of them reached borderline significance for a primary endpoint or statistical significance for secondary endpoints, subgroups or post-hoc analyses [ 3 – 5 , 7 , 45 , 46 ].
← all excerpts
Understanding heart failure with preserved ejection fraction: where are we today?
1
—
—